Telecoms.com Intelligence's Annual Industry Survey Highlights Increasing Importance Of 'Designed-For' B2B BSS Solutions
MDS Global Ltd, a leading BSS-as-a-Service provider, in collaboration with Telecoms.com Intelligence, today announced the findings of their 2019 Annual Industry Survey Report. In the report, dedicated and designed-for modern B2B BSS solutions were highlighted as a key requirement by Communication Service Providers (CSPs), with 84% of respondents identifying B2B as the area where enterprise customers will generate the highest revenue growth in 2020 and beyond.
Based on 540 responses to a survey, the report took an overview of the industry landscape over the last 12 months and provided projections for activity from 2020 and beyond. The OSS/BSS section of the survey highlighted that the B2B segments, including large enterprises (30%), small- and medium-sized enterprises (SMEs) (19%), small office/home office (SOHO) (17%), as well as public sector and wholesale partners, need to be served by a specialist B2B BSS platform. This platform should offer a dedicated digital engagement approach supporting personalised order, workflow and service management demands of enterprises, resellers and partners.
According to the survey, 50% of CSPs already have a separate platform to reflect this sector's demand, and 50% of these require a more digital approach to market engagement. 90% of CSPs agreed that the SME segment specifically requires real-time usage and control and the ability to configure, price and order services via online tools. Defined by service level agreements, business customers often demand higher levels of customisation, shorter time to market for new services, and tend to be less tolerant of failures. But at the same time, they are also less sensitive to price, compared with the consumer market.
Flexibility and customisation for both CSPs and enterprise is also especially important in 5G with its strong virtualisation and software-centric characteristics. The B2B sector is forecast to significantly outweigh the B2C sector as a major source of revenue from 5G services and the report reinforced how important 5G technology is in shaping and scheduling future projects. A staggering 97% of CSPs will use SDN/NFV environments to allow integrated services to be personalised, demonstrating that virtualisation will trigger major BSS change.
Gary Bunney, CEO, MDS Global said, "Currently, most BSS running in Communication Service Providers are hardwired to support traditional enterprise services and incorporate many offline business processes that require high-cost specialist resources to deliver constant change."
He continues, "Today’s market demands low-cost service agility. MDS Global is uniquely placed to assist CSPs in automating service engagement whilst enabling the opportunity that 5G and service personalisation brings to enterprises. We provide a dedicated B2B BSS-as-a-Service platform, decreasing the costs associated with operations, automating customer engagement and providing agility to ensure our CSP customers are able to invent, tailor and launch new services without the hindrance of engineering challenges."
MDS Global's B2B-on-Demand enables cost-efficiency and dedicated service delivery. Download the Telecoms.com Insight 2019 Annual Industry Survey here.
About MDS Global
MDS Global, a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions, look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.
Headquartered in the UK, MDS Global’s customers include BT Enterprise (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and NL), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).
For further information: www.mdsglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191216005010/en/
Contact information
Martine Naughton
MDS Global
Email: martine.naughton@mdsglobal.com
Tel: +44 (0) 7909 475815
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom